Real-world outcomes with recombinant factor VIIa treatment of acute bleeds in haemophilia patients with inhibitors: results from the international ONE registry-Reference-Cited by-同舟云学术

Real-world outcomes with recombinant factor VIIa treatment of acute bleeds in haemophilia patients with inhibitors: results from the international ONE registry

Published:2013-04-05 Issue:4 Volume:19 Page:571-577
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Chambost H.,Santagostino E.¹,Laffan M.²,Kavakli K.³,

Affiliation:

1. A. Bianchi Bonomi; Hemophilia and Thrombosis Center; Maggiore Hospital Policlinico; IRCCS Cà Granda Foundation; Milan; Italy

2. Imperial College London; Hammersmith Hospital; London; UK

3. Ege University Faculty of Medicine; Children's Hospital; Izmir; Turkey

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hae.12140/fullpdf

Reference17 articles.

1. NovoSeven® EU Summary of product characteristics (SmPC) http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000074/WC500030873.pdf

2. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (NovoSeven) in hemophiliacs with inhibitors;Key;Thromb Haemost,1998

3. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors;Abshire;J Thromb Haemost,2004

4. Dose effect and efficacy of rFVIIa in the treatment of hemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry;Parameswaran;Haemophilia,2005

5. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of haemoarthroses in haemophiliacs with inhibitors;Santagostino;J Thromb Haemost,2006

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. From coagulation to calm: factor VIIa’s microRNA magic trick;Journal of Thrombosis and Haemostasis;2024-02

2. Factor VIIa releases phosphatidylserine-enriched extracellular vesicles from endothelial cells by activating acid sphingomyelinase;Journal of Thrombosis and Haemostasis;2023-12

3. Current status and future prospects of activated recombinant coagulation factor VIIa, NovoSeven®, in the treatment of haemophilia and rare bleeding disorders;Annals of Hematology;2023-06-30

4. Factor VIIa induces extracellular vesicles from the endothelium: a potential mechanism for its hemostatic effect;Blood;2021-06-17

5. EPCR deficiency or function-blocking antibody protects against joint bleeding–induced pathology in hemophilia mice;Blood;2020-06-18